The introduction of second-generation androgen receptor antagonists (SG-ARAs) has
greatly impacted the treatment of metastatic prostate cancer, providing tolerable and …

Activation of the androgen receptor (AR) and AR-driven transcriptional programs is central to
the pathophysiology of prostate cancer. Despite successful translational efforts in targeting …

Circulating tumour DNA (ctDNA) in blood plasma is an emerging tool for clinical cancer
genotyping and longitudinal disease monitoring. However, owing to past emphasis on …

Neuroendocrine prostate cancer is a histological variant of prostate cancer that is
characterized by aggressiveness, poor clinical outcomes, and expression of neuroendocrine …

Purpose: Cross-resistance renders multiple lines of androgen receptor (AR) signaling
inhibitors increasingly futile in metastatic castration-resistant prostate cancer (mCRPC). We …

PURPOSE Nearly all men with prostate cancer treated with androgen receptor (AR)
signaling inhibitors (ARSIs) develop resistance via diverse mechanisms including …

Purpose: Men with metastatic castration-resistant prostate cancer (mCRPC) frequently
develop resistance to androgen receptor signaling inhibitor (ARSI) treatment; therefore, new …

Nucleotide‐based drugs, such as antisense oligonucleotides (ASOs), have unique
advantages in treating human diseases as they provide virtually unlimited ability to target …

Androgen receptor (AR) drives prostate cancer (PC) growth and progression, and targeting
AR signaling is the mainstay of pharmacological therapies for PC. Resistance develops …

Despite initial responses to hormone treatment, metastatic prostate cancer invariably
evolves to a lethal state. To characterize the intra-patient evolutionary relationships of …